Background The omicron BA.1 bivalent booster is used globally. Previous open-label studies
of the omicron BA.1 (Moderna mRNA-1273.214) booster showed superior neutralising …

Background & Aims Elbasvir (an NS5A inhibitor) and grazoprevir (an NS3/4A protease inhibitor)
are direct-acting antiviral agents recently approved in the United States for treatment of …

Plasma-derived polyclonal antibody therapeutics, such as intravenous immunoglobulin,
have multiple drawbacks, including low potency, impurities, insufficient supply and batch-to-…

Trends in Staphylococcus aureus infections are not well described. To calculate incidence in
overall S. aureus infection and invasive and noninvasive infections according to methicillin …

Background Omicron-containing bivalent boosters are available worldwide. Results of a
large, randomized, active-controlled study are presented. Methods This phase 3, randomized, …

Introduction In 2014–2016, an Ebola epidemic devastated Guinea; more than 3800 cases
and 2500 deaths were reported to the World Health Organization. In August 2015, as the …

The long-term efficacy of making resistance testing routinely available to clinicians has not
been established. We conducted a clinical trial at 6 US military hospitals in which volunteers …

Background Since 1999, the US Food and Drug Administration approved neuraminidase
and endonuclease inhibitors to treat uncomplicated outpatient influenza but not severe …

Background Behavioural research is needed to inform a ban on sales of filtered cigarettes
that could reduce plastic waste due to discarded filters. This study reports on differences in …

Anti-CTLA-4 antibodies such as ipilimumab were among the first immune-oncology agents
to show significantly improved outcomes for patients. However, existing anti-CTLA-4 …